BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Antonelli G, Scagnolari C, Moschella F, Proietti E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev 2015;26:121-31. [PMID: 25578520 DOI: 10.1016/j.cytogfr.2014.12.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Brzoska J, von Eick H, Hündgen M. Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta. Drug Res (Stuttg) 2020;70:291-7. [PMID: 32443163 DOI: 10.1055/a-1170-4395] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Gessani S, Belardelli F. Type I Interferons as Joint Regulators of Tumor Growth and Obesity. Cancers (Basel) 2021;13:E196. [PMID: 33430520 DOI: 10.3390/cancers13020196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, Wettengel J, Li JB, Stafforst T. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol 2019;37:133-8. [PMID: 30692694 DOI: 10.1038/s41587-019-0013-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
4 Lu C, Wen T, Zheng M, Liu D, Quan G, Pan X, Wu C. Poly(Ethylene Glycol) Crosslinked Multi-Armed Poly(l-Lysine) with Encapsulating Capacity and Antimicrobial Activity for the Potential Treatment of Infection-Involved Multifactorial Diseases. Pharmaceutics 2020;12:E47. [PMID: 31935837 DOI: 10.3390/pharmaceutics12010047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Oppenheim JJ. The Future of the Cytokine Discipline. Cold Spring Harb Perspect Biol 2018;10:a028498. [PMID: 28847901 DOI: 10.1101/cshperspect.a028498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Aricò E, Bracci L, Castiello L, Gessani S, Belardelli F. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? Cytokine Growth Factor Rev 2020;54:43-50. [PMID: 32665127 DOI: 10.1016/j.cytogfr.2020.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
7 Blank T, Prinz M. Type I interferon pathway in CNS homeostasis and neurological disorders. Glia 2017;65:1397-406. [PMID: 28519900 DOI: 10.1002/glia.23154] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 12.8] [Reference Citation Analysis]
8 Mousavi SM, Hashemi SA, Parvin N, Gholami A, Ramakrishna S, Omidifar N, Moghadami M, Chiang WH, Mazraedoost S. Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial. Drug Metab Rev 2021;53:141-70. [PMID: 33138652 DOI: 10.1080/03602532.2020.1845201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov 2018;17:19-33. [PMID: 29075002 DOI: 10.1038/nrd.2017.194] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
10 Brezgin S, Kostyusheva A, Bayurova E, Volchkova E, Gegechkori V, Gordeychuk I, Glebe D, Kostyushev D, Chulanov V. Immunity and Viral Infections: Modulating Antiviral Response via CRISPR-Cas Systems. Viruses 2021;13:1373. [PMID: 34372578 DOI: 10.3390/v13071373] [Reference Citation Analysis]
11 Chen YC, Figliozzi RW, Hsia SV. Pilot Analyses of Interferon Subtype Expression Profiles in Patients with Herpes Zoster or Postherpetic Neuralgia. Viral Immunol 2021. [PMID: 33857386 DOI: 10.1089/vim.2020.0295] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Goncharova EP, Sen'kova AV, Savin IA, Kabilova TO, Zenkova MA, Vlassov VV, Chernolovskaya EL. Immunostimulating RNA Delivered by P1500 PEGylated Cationic Liposomes Limits Influenza Infection in C57Bl/6 Mice. Pharmaceutics 2020;12:E875. [PMID: 32937880 DOI: 10.3390/pharmaceutics12090875] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Palermo E, Di Carlo D, Sgarbanti M, Hiscott J. Type I Interferons in COVID-19 Pathogenesis. Biology (Basel) 2021;10:829. [PMID: 34571706 DOI: 10.3390/biology10090829] [Reference Citation Analysis]
14 Razaghi A, Brusselaers N, Björnstedt M, Durand-Dubief M. Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy. Neoplasia 2021;23:1059-68. [PMID: 34555656 DOI: 10.1016/j.neo.2021.08.004] [Reference Citation Analysis]
15 Xin XL, Zhang R, Yuan XM, Liu L. Mechanisms of IFNalpha-1a-Induced Apoptosis in a Laryngeal Cancer Cell Line. Med Sci Monit 2019;25:7100-14. [PMID: 31542790 DOI: 10.12659/MSM.917097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Glitza IC, Goff SL, Ross M, Margolin K. And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32243202 DOI: 10.1200/EDBK_79437] [Reference Citation Analysis]
17 Santibañez A, Paine D, Parra M, Muñoz C, Valdes N, Zapata C, Vargas R, Gonzalez A, Tello M. Oral Administration of Lactococcus lactis Producing Interferon Type II, Enhances the Immune Response Against Bacterial Pathogens in Rainbow Trout. Front Immunol 2021;12:696803. [PMID: 34248997 DOI: 10.3389/fimmu.2021.696803] [Reference Citation Analysis]
18 Duguet F, Ortega-Ferreira C, Fould B, Darville H, Berger S, Chomel A, Leclerc G, Kisand K, Haljasmägi L, Hayday AC, Desvaux E, Nony E, Moingeon P, De Ceuninck F. S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. J Transl Autoimmun 2021;4:100093. [PMID: 33748735 DOI: 10.1016/j.jtauto.2021.100093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Opdenakker G, Van Damme J. Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity. Cytokine Growth Factor Rev 2021;58:134-40. [PMID: 33563543 DOI: 10.1016/j.cytogfr.2021.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bracci L, Sistigu A, Proietti E, Moschella F. The added value of type I interferons to cytotoxic treatments of cancer. Cytokine Growth Factor Rev 2017;36:89-97. [PMID: 28693974 DOI: 10.1016/j.cytogfr.2017.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
21 Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, Butler KM, Morfopoulou S, Brown JR, Hubank M, Connell J, Gavin PJ, McMahon C, Dempsey E, Lynch NE, Jacques TS, Valappil M, Cant AJ, Breuer J, Engelhardt KR, Randall RE, Hambleton S. Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med. 2015;7:307ra154. [PMID: 26424569 DOI: 10.1126/scitranslmed.aac4227] [Cited by in Crossref: 111] [Cited by in F6Publishing: 98] [Article Influence: 18.5] [Reference Citation Analysis]
22 Premraj A, Aleyas AG, Nautiyal B, Rasool TJ. Camelid type I interferons: Identification and functional characterization of interferon alpha from the dromedary camel (Camelus dromedarius). Mol Immunol 2020;119:132-43. [PMID: 32014632 DOI: 10.1016/j.molimm.2020.01.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Scagnolari C, Antonelli G. Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine Growth Factor Rev 2018;40:19-31. [PMID: 29576284 DOI: 10.1016/j.cytogfr.2018.03.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
24 Ciccolella M, Andreone S, Mancini J, Sestili P, Negri D, Pacca AM, D'Urso MT, Macchia D, Canese R, Pang K, SaiYing Ko T, Decadt Y, Schiavoni G, Mattei F, Belardelli F, Aricò E, Bracci L. Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. Cells 2021;10:845. [PMID: 33917958 DOI: 10.3390/cells10040845] [Reference Citation Analysis]
25 Boudinot P, Langevin C, Secombes CJ, Levraud JP. The Peculiar Characteristics of Fish Type I Interferons. Viruses 2016;8:E298. [PMID: 27827855 DOI: 10.3390/v8110298] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
26 Aricò E, Bracci L, Castiello L, Urbani F, Casanova JL, Belardelli F. Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19. Cytokine Growth Factor Rev 2021:S1359-6101(21)00092-7. [PMID: 34955389 DOI: 10.1016/j.cytogfr.2021.12.001] [Reference Citation Analysis]
27 Saleiro D, Kosciuczuk EM, Platanias LC. Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses. Cytokine Growth Factor Rev 2016;29:17-22. [PMID: 27068414 DOI: 10.1016/j.cytogfr.2016.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
28 Spolaore B, Raboni S, Satwekar AA, Grigoletto A, Mero A, Montagner IM, Rosato A, Pasut G, Fontana A. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues. Bioconjug Chem 2016;27:2695-706. [PMID: 27731976 DOI: 10.1021/acs.bioconjchem.6b00468] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
29 Paul F, Pellegrini S, Uzé G. IFNA2: The prototypic human alpha interferon. Gene 2015;567:132-7. [PMID: 25982860 DOI: 10.1016/j.gene.2015.04.087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
30 Miller SE, Yamada Y, Patel N, Suárez E, Andrews C, Tau S, Luke BT, Cachau RE, Schneider JP. Electrostatically Driven Guanidinium Interaction Domains that Control Hydrogel-Mediated Protein Delivery In Vivo. ACS Cent Sci 2019;5:1750-9. [PMID: 31807676 DOI: 10.1021/acscentsci.9b00501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]